<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Tanaka S</submitter><funding>POE FEDER 2014-20</funding><funding>Université de La Réunion</funding><pagination>754</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9029957</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>10(4)</volume><pubmed_abstract>High-density lipoproteins (HDLs) have multiple endothelioprotective properties. During SARS-CoV-2 infection, HDL-cholesterol (HDL-C) concentration is markedly reduced, and studies have described severe impairment of the functionality of HDL particles. Here, we report a multi-omic investigation of the first administration of recombinant HDL (rHDL) particles in a severe COVID-19 patient in an intensive care unit. Plasma ApoA1 increased and HDL-C decreased after each recombinant HDL injection, suggesting that these particles were functional in terms of reverse cholesterol transport. The proportion of large HDL particles also increased after injection of recombinant HDL. Shotgun proteomics performed on HDLs isolated by ultracentrifugation indicated that ApoA1 was more abundant after injections</pubmed_abstract><journal>Biomedicines</journal><pubmed_title>First Recombinant High-Density Lipoprotein Particles Administration in a Severe ICU COVID-19 Patient, a Multi-Omics Exploratory Investigation.</pubmed_title><pmcid>PMC9029957</pmcid><funding_grant_id>COVID-19 emergency seed funding</funding_grant_id><funding_grant_id>RE0027601</funding_grant_id><funding_grant_id>RE20201437</funding_grant_id><pubmed_authors>Atchade E</pubmed_authors><pubmed_authors>Robert T</pubmed_authors><pubmed_authors>Lortat-Jacob B</pubmed_authors><pubmed_authors>Tran-Dinh A</pubmed_authors><pubmed_authors>Zappella N</pubmed_authors><pubmed_authors>de Chaisemartin L</pubmed_authors><pubmed_authors>Begue F</pubmed_authors><pubmed_authors>Veeren B</pubmed_authors><pubmed_authors>Tashk P</pubmed_authors><pubmed_authors>Meilhac O</pubmed_authors><pubmed_authors>Tanaka S</pubmed_authors><pubmed_authors>Kramer L</pubmed_authors><pubmed_authors>Faille D</pubmed_authors><pubmed_authors>Montravers P</pubmed_authors></additional><is_claimable>false</is_claimable><name>First Recombinant High-Density Lipoprotein Particles Administration in a Severe ICU COVID-19 Patient, a Multi-Omics Exploratory Investigation.</name><description>High-density lipoproteins (HDLs) have multiple endothelioprotective properties. During SARS-CoV-2 infection, HDL-cholesterol (HDL-C) concentration is markedly reduced, and studies have described severe impairment of the functionality of HDL particles. Here, we report a multi-omic investigation of the first administration of recombinant HDL (rHDL) particles in a severe COVID-19 patient in an intensive care unit. Plasma ApoA1 increased and HDL-C decreased after each recombinant HDL injection, suggesting that these particles were functional in terms of reverse cholesterol transport. The proportion of large HDL particles also increased after injection of recombinant HDL. Shotgun proteomics performed on HDLs isolated by ultracentrifugation indicated that ApoA1 was more abundant after injections</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Mar</publication><modification>2025-04-19T09:18:28.121Z</modification><creation>2024-12-03T16:06:31.956Z</creation></dates><accession>S-EPMC9029957</accession><cross_references><pubmed>35453504</pubmed><doi>10.3390/biomedicines10040754</doi></cross_references></HashMap>